ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negative Hyperselection of Patients With RAS WT mCRC for Panitumumab

328 views
January 26, 2023
Comments 0
Login to view comments. Click here to Login